“One-year adjusted HR for mortality was 1.92 (95% CI 1.81-2.04) for mild frailty, 3.10 (95% CI 2.91-3.31) for moderate frailty and 4.52 (95% CI 4.16-4.91) for severe frailty.”
Electronic frailty index is linked with higher length of stay in humans (hospitalized COVID-19 patients, controlling for age and sex) (β = 2.00, 95% CI 1.65-2.34).
“and a longer length of stay (β-coefficient = 2.00; 1.65-2.34)”
Humanshospitalized COVID-19 patients, controlling for age and sex10% incrementn = 3,980
Days alive and out of hospital in the first 30 days
↓downin humans1
1 study
Electronic frailty index is linked with lower days alive and out of hospital in the first 30 days in older adults receiving CAR-T therapy (β= -3.79, p<0.01).
Electronic frailty index is linked with better risk prediction discrimination in humans (Compared with Hospital Frailty Risk Score and Charlson Comorbidity Index).
“Across all outcomes, the eFI showed greater model discrimination than HFRS and CCI.”
HumansCompared with Hospital Frailty Risk Score and Charlson Comorbidity Indexn = 193,629
Electronic frailty index is linked with better model performance in humans (type 2 diabetes) (standard model vs. EFI; 0.616 vs. 0.631 and 0.776 vs. 0.778).
“Incorporating eFI may improve model performance for both mortality and admission outcomes”
Electronic frailty index is linked with worse physical function in humans (metastatic non-small-cell lung cancer on immunotherapy) (mean 83.9 fit vs 74.8 pre-frail vs 60.0 frail, P = .04).
“Pre-frail and frail patients had significantly lower physical function scores (mean 83.9 fit vs 74.8 pre-frail vs 60.0 frail, P = .04)”
Humansmetastatic non-small-cell lung cancer on immunotherapy60% womensn = 60
The American journal of hospice & palliative care·
Chemotherapy cycles received
↔no changein humans1
1 study
Electronic frailty index was not clearly linked with chemotherapy cycles received in humans (acute myeloid leukemia with less-intensive therapy and survival ≥6 months) (p = 0.97).
“For those with less-intensive therapy who lived ≥6 months, eFI category was not associated with the number of chemotherapy cycles received (p = 0.97).”
Humansacute myeloid leukemia with less-intensive therapy and survival ≥6 months
Electronic frailty index is associated with mortality in humans (Pre-frail HR 1.7 (95% CI 1.2–2.3); frail HR 2.0 (1.3–3.1); not calculable HR 2.6 (1.7–4.0), versus fit).
“EHR-derived frailty was associated with hospitalization and survival”
HumansNewly diagnosed lung, colorectal, or breast cancer treated with chemotherapy; adjusted comparisons with fit patientsn = 509
Electronic frailty index is associated with mortality in humans (Per 10% higher baseline frailty; adjusted for socioeconomic-related covariates) (HR 1.44 (95% CI 1.38–1.51) per 10% higher baseline frailty; before socioeconomic adjustment: HR 2.00 (1.93–2.07)).
“although the magnitude of this association decreased when adjusting for socioeconomic-related covariates (HR (95% CI)=1.44 (1.38-1.51)).”
Electronic frailty index predicts mortality in humans (colorectal cancer treated with chemotherapy, severely frail, ≥70 y.o. vs <70 y.o) (OR 2.04 (95% CI 1.58-2.64)).
“The risk of dying within 30 days of chemotherapy in severely frail patients with colorectal cancer ≥70 y.o. was twice that of the <70 y.o. (OR 2.04 -95% CI 1.58-2.64”
Humanscolorectal cancer treated with chemotherapy, severely frail, ≥70 y.o. vs <70 y.o30 days
Electronic frailty index predicts mortality in humans (aHR 1.77, 3.31, 6.65 (p < 0.005)).
“adjusted hazard ratios of mortality of the mild, moderate and severe frail group were 1.77, 3.31 and 6.65 respectively and they were all statistically higher than the fit group. (p < 0.005)”
Electronic frailty index is associated with hospitalization in humans (Newly diagnosed lung, colorectal, or breast cancer treated with chemotherapy) (24% fit, 42% pre-frail, 62% frail, 50% non-calculable).
“Six-month hospitalization increased with frailty: 24% (fit), 42% (pre-frail), 62% (frail), and 50% (non-calculable) (P<.0001).”
HumansNewly diagnosed lung, colorectal, or breast cancer treated with chemotherapy6 monthsn = 509
Electronic frailty index predicts hospitalization in humans (ED presentation) (OR 3.55, P < 0.0001).
“adjusted odds ratios (OR) for hospitalization, in-hospital mortality, ICU admission, and ED readmission rose to 3.55, 14.15, 4.70, and 2.22, respectively (P < 0.0001)”
Electronic frailty index predicts in-hospital mortality in humans (ED presentation) (OR 14.15, P < 0.0001).
“adjusted odds ratios (OR) for hospitalization, in-hospital mortality, ICU admission, and ED readmission rose to 3.55, 14.15, 4.70, and 2.22, respectively (P < 0.0001)”
Electronic frailty index is linked with a higher risk of in-hospital mortality in humans (hospitalized COVID-19 patients, controlling for age and sex) (OR 2.95, 95% CI 2.42-3.62).
“a 10% increment in the eFI was significantly associated with higher risks of in-hospital mortality (odds ratio = 2.95; 95% confidence interval = 2.42-3.62)”
Humanshospitalized COVID-19 patients, controlling for age and sex10% incrementn = 3,980
The journals of gerontology. Series A, Biological sciences and medical sciences·
Electronic frailty index is associated with in-hospital mortality in humans (inpatients with eFI≥0.15; adjusted for age, sex, and operation) (OR = 19.97).
“an eFI≥0.15 showed an independent association with long hospital stay (odds ratio [OR] = 2.889, P < 0.001) and death in hospital (OR = 19.97, P < 0.001).”
Humansinpatients with eFI≥0.15; adjusted for age, sex, and operation
Electronic frailty index is linked with a higher risk of 30-day mortality in humans (hospitalized COVID-19 patients, controlling for age and sex) (HR 2.39, 95% CI 2.08-2.74).
“30-day mortality (hazard ratio [HR] = 2.39; 2.08-2.74)”
Humanshospitalized COVID-19 patients, controlling for age and sex10% increment30-dayn = 3,980
The journals of gerontology. Series A, Biological sciences and medical sciences·
Electronic frailty index predicts 30-day mortality in humans (patients admitted to nine public hospitals for heart failure) (AUC 0.90).
“The area under the curve from a five-fold cross validation was 0.90 for gradient boosting and 0.87 and 0.86 for decision tree and logistic regression in predicting 30 day mortality.”
Humanspatients admitted to nine public hospitals for heart failure30 dayn = 8,893
Electronic frailty index is linked with a higher risk of 6-month mortality in humans (hospitalized COVID-19 patients, controlling for age and sex) (HR 2.29, 95% CI 2.04-2.56).
“6-month mortality (HR = 2.29; 2.04-2.56)”
Humanshospitalized COVID-19 patients, controlling for age and sex10% increment6-monthn = 3,980
Electronic frailty index is linked with a higher risk of major adverse cardiovascular events in older adults with atrial fibrillation (HR 1.92, 95% CI 1.62–2.28).
“highest quartile of cumulative frailty burden was associated with a 92% higher risk of MACEs (hazard ratio [HR] 1.92, 95% confidence interval [CI] 1.62–2.28; P < 0.001)”
Health technology assessment (Winchester, England)·
Emergency department attendance/hospitalization with fall/fracture
↑upin humans1
1 study
Electronic frailty index predicts emergency department attendance/hospitalization with fall/fracture in humans (external validation) (C-statistic 0.83).
An aging measure developed in 320,891 UK Biobank participants was linked to all 20 non-cancer diseases assessed in two UK datasets.An aging measure developed in 320,891 UK Biobank participants was linked to all 20 non-cancer diseases assessed in two UK datasets.
Stopping statins was linked to a hospitalization risk 37.6 per 1,000 patients higher at one year than continuing them.Stopping statins was linked to a hospitalization risk 37.6 per 1,000 patients higher at one year than continuing them.
Very frail older patients had worse overall survival (HR=1.64) and event-free survival (HR=2.02) after CAR-T therapy than robust or prefrail peers.Very frail older patients had worse overall survival (HR=1.64) and event-free survival (HR=2.02) after CAR-T therapy than robust or prefrail peers.